上海医药：普瑞巴林胶囊获得菲律宾药品注册证书

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Philippines Food and Drug Administration for its Pregabalin capsules, allowing the product to be marketed in the Philippines [1] Group 1: Product Approval and Market Impact - The Pregabalin capsules are primarily used for treating postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1] - The approval marks the company's qualification to sell the drug in the Philippines, which is expected to positively impact the company's expansion into overseas markets and accumulate valuable experience [1] Group 2: Financial and Market Data - The total sales amount for Pregabalin capsules in the Philippines market across three specifications (50mg, 75mg, 150mg) is reported to be $13.37 million [1] - The research and development expenses incurred for launching the product in the Southeast Asian market (including Thailand, Singapore, Malaysia, and the Philippines) amount to approximately RMB 2.19 million [1]